US FDA gets tough on financial disclosures by clinical investigators
This article was originally published in SRA
The US Food and Drug Administration has substantially revised its guidance on the disclosure of financial interests by clinical investigators and is seeking stakeholder feedback on the draft document1,2. The revised guidance addresses concerns that the FDA does not do enough to guard against financial conflicts of interest among physicians, who carry out clinical trials of pharmaceuticals and medical devices that have yet to receive marketing authorisation.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.